EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate

Johan Maertens, Monica Slavin iD, Martin Hoenigl, George R Thompson iD, Malcolm Richardson, Cornelia Lass-Flörl

Journal of Antimicrobial Chemotherapy · 01.08.2024 · 79 (8) · 1786-1793

DOI: 10.1093/jac/dkae158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 01.08.2024. Verfasst von Johan Maertens und 5 weiteren Autor:innen. Beteiligte Einrichtung: University Hospitals Leuven, Department of Haematology and ECMM Excellence Center of Medical Mycology, Campus Gasthuisberg Leuven, Belgium. Hauptthemen laut MEDLINE: Invasive Fungal Infections, Clinical Trials as Topic, Antifungal Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shionogi B.V., London, UK, F2G Ltd, Manchester, UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Invasive Fungal InfectionsClinical Trials as TopicAntifungal AgentsHumansTreatment Outcome

Substanzen

Antifungal Agents

Autor:innen und Institutionen

  • University Hospitals Leuven, Department of Haematology and ECMM Excellence Center of Medical Mycology, Campus Gasthuisberg Leuven, Belgium.
  • Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
  • Division of Infectious Diseases, ECMM Excellence Center of Medical Mycology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Division of Infectious Diseases, and Departments of Internal Medicine and Medical Microbiology and Immunology, University of California-Davis, Sacramento, CA, USA.
  • Mycology Reference Centre Manchester, ECMM Excellence Center of Medical Mycology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Christian-Doppler Laboratory for Invasive Fungal Infections, Institute of Hygiene and Medical Microbiology, ECMM Excellence Center of Medical Mycology, Medical University of Innsbruck, Innsbruck, Austria.

ORCID-Profile: Monica Slavin, George R Thompson

Förderung

  • Shionogi B.V., London, UK
  • F2G Ltd, Manchester, UK

Zitieren

APA

Maertens, J., Slavin, M., Hoenigl, M., Thompson, G. R., Richardson, M., & Lass-Flörl, C. (2024). Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate. Journal of Antimicrobial Chemotherapy, 79(8), 1786-1793. https://doi.org/10.1093/jac/dkae158

Vancouver

Maertens J, Slavin M, Hoenigl M, Thompson GR, Richardson M, Lass-Flörl C. Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate. Journal of Antimicrobial Chemotherapy. 2024;79(8):1786-1793. doi:10.1093/jac/dkae158

BibTeX
@article{Maertens2024,
  author = {Maertens, Johan and Slavin, Monica and Hoenigl, Martin and Thompson, George R and Richardson, Malcolm and Lass-Flörl, Cornelia},
  title = {Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases—a debate},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {8},
  pages = {1786--1793},
  doi = {10.1093/jac/dkae158}
}
Kostenlos starten →